Engineered immune cells target hard-to-treat blood cancers in kids and young adults

NCT ID NCT04571138

First seen Feb 20, 2026 · Last updated May 01, 2026 · Updated 7 times

Summary

This study tests a new treatment for children and young adults up to age 30 whose leukemia or lymphoma has come back or not responded to standard therapy. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack cancer cells carrying a protein called CD22. The study has two parts: the first checks safety and the right dose, and the second measures how well the treatment works. Up to 42 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Children's Hospital Los Angeles

    Los Angeles, California, 90027, United States

  • Riley Hospital for Children

    Indianapolis, Indiana, 46202, United States

  • Seattle Children's Hospital

    Seattle, Washington, 98105, United States

  • Texas Children's Hospital

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.